BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32591499)

  • 1. Repurposing anthelmintic agents to eradicate resistant leukemia.
    Mezzatesta C; Abduli L; Guinot A; Eckert C; Schewe D; Zaliova M; Vinti L; Marovca B; Tsai YC; Jenni S; Aguade-Gorgorio J; von Stackelberg A; Schrappe M; Locatelli F; Stanulla M; Cario G; Bourquin JP; Bornhauser BC
    Blood Cancer J; 2020 Jun; 10(6):72. PubMed ID: 32591499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
    Frismantas V; Dobay MP; Rinaldi A; Tchinda J; Dunn SH; Kunz J; Richter-Pechanska P; Marovca B; Pail O; Jenni S; Diaz-Flores E; Chang BH; Brown TJ; Collins RH; Uhrig S; Balasubramanian GP; Bandapalli OR; Higi S; Eugster S; Voegeli P; Delorenzi M; Cario G; Loh ML; Schrappe M; Stanulla M; Kulozik AE; Muckenthaler MU; Saha V; Irving JA; Meisel R; Radimerski T; Von Stackelberg A; Eckert C; Tyner JW; Horvath P; Bornhauser BC; Bourquin JP
    Blood; 2017 Mar; 129(11):e26-e37. PubMed ID: 28122742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
    Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
    Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
    Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
    Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
    Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
    Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
    Zhao H; Shi P; Deng M; Jiang Z; Li Y; Kannappan V; Wang W; Li P; Xu B
    Oncotarget; 2016 Dec; 7(51):85515-85528. PubMed ID: 27888802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
    Bornhauser BC; Bonapace L; Lindholm D; Martinez R; Cario G; Schrappe M; Niggli FK; Schäfer BW; Bourquin JP
    Blood; 2007 Sep; 110(6):2084-91. PubMed ID: 17537996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the bone marrow microenvironment in acute leukemia.
    Karantanou C; Godavarthy PS; Krause DS
    Leuk Lymphoma; 2018 Nov; 59(11):2535-2545. PubMed ID: 29431560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment.
    Nair RR; Piktel D; Hathaway QA; Rellick SL; Thomas P; Saralkar P; Martin KH; Geldenhuys WJ; Hollander JM; Gibson LF
    Pharm Res; 2020 Jan; 37(3):43. PubMed ID: 31989336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
    Zhang C; Zhang Z; Zhang S; Wang W; Hu P
    Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
    Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dormancy Stems the Tide of Chemotherapy.
    Pal D; Heidenreich O; Vormoor J
    Cancer Cell; 2016 Dec; 30(6):825-826. PubMed ID: 27960078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
    Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
    Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
    Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
    Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia.
    Singh H; Shelat AA; Singh A; Boulos N; Williams RT; Guy RK
    J Biomol Screen; 2014 Jan; 19(1):158-67. PubMed ID: 23989453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia.
    Yuan N; Song L; Zhang S; Lin W; Cao Y; Xu F; Fang Y; Wang Z; Zhang H; Li X; Wang Z; Cai J; Wang J; Zhang Y; Mao X; Zhao W; Hu S; Chen S; Wang J
    Haematologica; 2015 Mar; 100(3):345-56. PubMed ID: 25512644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
    Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.